According to Zacks, “Aerie reported mixed results for the fourth quarter wherein loss was narrower than expected while sales missed estimates. Rhopressa sales missed estimates due to higher rebates. Nevertheless, the approval of the second drug, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan, has boosted the company’s portfolio and should propel sales in the coming quarters. We are also impressed with the company’s efforts to develop and boost its pipeline. However, shares have underperformed the industry in the past six months. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta, among others.”
A number of other research analysts have also commented on AERI. ValuEngine upgraded shares of Aerie Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, May 9th. Canaccord Genuity lowered their price objective on shares of Aerie Pharmaceuticals from $65.00 to $56.00 and set a buy rating on the stock in a research note on Friday, May 10th. BidaskClub lowered shares of Aerie Pharmaceuticals from a sell rating to a strong sell rating in a research note on Wednesday, March 27th. Cantor Fitzgerald set a $85.00 price objective on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, February 26th. Finally, Piper Jaffray Companies set a $76.00 price objective on shares of Aerie Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, May 8th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. Aerie Pharmaceuticals currently has an average rating of Buy and an average target price of $75.42.
Shares of NASDAQ AERI traded down $0.33 during mid-day trading on Thursday, reaching $40.21. 9,399 shares of the company traded hands, compared to its average volume of 594,512. Aerie Pharmaceuticals has a fifty-two week low of $32.18 and a fifty-two week high of $74.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.47 and a quick ratio of 3.27. The firm has a market capitalization of $1.84 billion, a PE ratio of -8.66 and a beta of 0.82.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.78) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.13. Aerie Pharmaceuticals had a negative net margin of 684.56% and a negative return on equity of 93.96%. The business had revenue of $10.85 million for the quarter, compared to analyst estimates of $12.66 million. Sell-side analysts anticipate that Aerie Pharmaceuticals will post -2.6 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Daruma Capital Management LLC lifted its stake in shares of Aerie Pharmaceuticals by 60.4% in the 1st quarter. Daruma Capital Management LLC now owns 747,221 shares of the company’s stock valued at $35,493,000 after purchasing an additional 281,240 shares during the last quarter. Morgan Stanley lifted its stake in shares of Aerie Pharmaceuticals by 13.9% in the 1st quarter. Morgan Stanley now owns 508,912 shares of the company’s stock valued at $24,174,000 after purchasing an additional 61,976 shares during the last quarter. Coastal Investment Advisors Inc. acquired a new stake in shares of Aerie Pharmaceuticals in the 1st quarter valued at $33,000. Goldman Sachs Group Inc. lifted its stake in shares of Aerie Pharmaceuticals by 76.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 168,459 shares of the company’s stock valued at $8,002,000 after purchasing an additional 73,121 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Aerie Pharmaceuticals by 1.1% in the 1st quarter. Wellington Management Group LLP now owns 6,318,560 shares of the company’s stock valued at $300,132,000 after purchasing an additional 65,861 shares during the last quarter.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Further Reading: What is a Lock-Up Period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.